Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PRPO 
Precipio Inc (PRPO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: PRPO (3-star) is a STRONG-BUY. BUY since 6 days. Simulated Profits (9.92%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $19
1 Year Target Price $19
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 87.92% | Avg. Invested days 37 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 31.58M USD | Price to earnings Ratio - | 1Y Target Price 19 |
Price to earnings Ratio - | 1Y Target Price 19 | ||
Volume (30-day avg) 1 | Beta 1.09 | 52 Weeks Range 3.90 - 22.38 | Updated Date 09/14/2025 |
52 Weeks Range 3.90 - 22.38 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.19 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -8.48% | Operating Margin (TTM) -14.57% |
Management Effectiveness
Return on Assets (TTM) -9.05% | Return on Equity (TTM) -14.76% |
Valuation
Trailing PE - | Forward PE 15.43 | Enterprise Value 33062888 | Price to Sales(TTM) 1.49 |
Enterprise Value 33062888 | Price to Sales(TTM) 1.49 | ||
Enterprise Value to Revenue 1.56 | Enterprise Value to EBITDA -1.15 | Shares Outstanding 1619580 | Shares Floating 1446175 |
Shares Outstanding 1619580 | Shares Floating 1446175 | ||
Percent Insiders 12.81 | Percent Institutions 5.75 |
Upturn AI SWOT
Precipio Inc
Company Overview
History and Background
Precipio, Inc. was founded in 2011. It focuses on cancer diagnostics and offers solutions to improve accuracy and efficiency in cancer diagnosis.
Core Business Areas
- IV Cell: Offers IV Cell, a media for cell culture that supports high-density cell growth, specifically aimed at optimizing antibody production.
- HemeScreen: Provides HemeScreen, a comprehensive diagnostic service for hematological malignancies, delivering accurate and rapid results.
- CAP Accreditation Program: Provides consulting services to pathology labs to help them attain College of American Pathologists (CAP) accreditation.
- CRO Services: Precipio offers its own CRO services with its CRO partner in India. It is a fully-owned subsidiary of Antal International Network
Leadership and Structure
Ilyas Rafiq is the current Chief Executive Officer. The company operates with a management team overseeing different functional areas.
Top Products and Market Share
Key Offerings
- IV Cell: IV-Cell' is a transformative bioprocessing and cell culture platform that delivers unprecedented cell yields and dramatically reduces costs. Market share data is unavailable. Competitors include Thermo Fisher Scientific (TMO) and Merck KGaA (MRK).
- HemeScreen: HemeScreen offers a comprehensive diagnostic service for hematological malignancies. Market share data is unavailable. Competitors include NeoGenomics (NEO) and Quest Diagnostics (DGX).
Market Dynamics
Industry Overview
The cancer diagnostics market is driven by increasing cancer prevalence, technological advancements, and growing demand for personalized medicine.
Positioning
Precipio aims to differentiate itself through innovative diagnostic solutions, focusing on improving accuracy and efficiency in cancer diagnosis.
Total Addressable Market (TAM)
The global cancer diagnostics market is estimated to be worth hundreds of billions of dollars. Precipio, with its niche focus, targets a segment of this market.
Upturn SWOT Analysis
Strengths
- Innovative diagnostic solutions
- Focus on improving accuracy in cancer diagnosis
- Strategic partnerships
Weaknesses
- Limited market share
- Reliance on key product lines
- Financial constraints
- Small company size
Opportunities
- Expanding product portfolio
- Entering new geographic markets
- Strategic acquisitions
- Partnerships with larger diagnostic companies
Threats
- Competition from larger diagnostic companies
- Regulatory changes
- Technological advancements by competitors
- Economic downturns
Competitors and Market Share
Key Competitors
- Thermo Fisher Scientific (TMO)
- NeoGenomics (NEO)
- Quest Diagnostics (DGX)
Competitive Landscape
Precipio faces competition from larger, more established players. Its competitive advantage lies in its innovative diagnostic solutions and niche market focus.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by expansion of its product offerings and strategic partnerships.
Future Projections: Future growth depends on successful market penetration and innovation.
Recent Initiatives: Recent initiatives include the launch of new diagnostic products and strategic alliances.
Summary
Precipio is a smaller company focused on niche segments of cancer diagnostics. Its strengths lie in its innovative products, however, it is weak due to its smaller size and reliance on a few products. Strategic acquisitions could help the company with more revenue streams. It faces tough competition from larger established companies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Industry reports
- Analyst estimates
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Market share estimates may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Precipio Inc
Exchange NASDAQ | Headquaters New Haven, CT, United States | ||
IPO Launch date 2000-07-18 | Founder, President, CEO & Director Mr. Ilan Danieli | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 54 | Website https://www.precipiodx.com |
Full time employees 54 | Website https://www.precipiodx.com | ||
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.